Flu Vaccine Momentum: Social media discussions spotlight Moderna's FDA expedited review for its flu vaccine, with a decision slated for August, fueling optimism among investors. Institutional moves, including Fidelity and BNP Paribas boosting stakes and Goldman Sachs lifting its price target, have propelled shares up significantly from early 2026 levels. Once dismissed as a one-hit wonder, the stock now ranks among the S&P 500's top performers despite distance from its peak.
Technical Resilience: Traders highlight the stock respecting key weekly moving average supports near $46-$50, with recent green candles and RSI climbing above 50 on rising volume. After plummeting from nearly $500 to sub-$12 lows, the bounce to around $53 tests overhead resistance at $65-$90. Debates center on whether a bull flag pattern emerges or if it rolls over below critical levels.
Short Interest Pressure: Despite 10% revenue growth guidance, Moderna leads S&P 500 names in short interest, reflecting persistent doubts. Critics question mRNA flu shot efficacy and cite patent disputes, while bulls eye patent resolutions as catalysts. Sentiment remains divided on the biotech's path forward.
Note: This discussion summary was generated from an AI condensation of post data.
Moderna Insider Trading Activity
Moderna insiders have traded $MRNA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) sold 160,009 shares for an estimated $7,814,839
- SHANNON THYME KLINGER (Chief Legal Officer) sold 13,885 shares for an estimated $726,046
- NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
- ABBAS HUSSAIN sold 504 shares for an estimated $13,910
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Moderna Hedge Fund Activity
We have seen 261 institutional investors add shares of Moderna stock to their portfolio, and 318 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 15,741,014 shares (+127.9%) to their portfolio in Q4 2025, for an estimated $464,202,502
- CAPITAL WORLD INVESTORS added 12,828,040 shares (+inf%) to their portfolio in Q4 2025, for an estimated $378,298,899
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,254,709 shares (-79.7%) from their portfolio in Q4 2025, for an estimated $184,451,368
- ALYESKA INVESTMENT GROUP, L.P. added 3,228,531 shares (+inf%) to their portfolio in Q4 2025, for an estimated $95,209,379
- BNP PARIBAS FINANCIAL MARKETS added 3,058,933 shares (+279.7%) to their portfolio in Q4 2025, for an estimated $90,207,934
- BLACKROCK, INC. added 2,977,816 shares (+10.1%) to their portfolio in Q4 2025, for an estimated $87,815,793
- CITADEL ADVISORS LLC removed 1,408,601 shares (-70.9%) from their portfolio in Q4 2025, for an estimated $41,539,643
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Moderna Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 3 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
- Leerink Partners issued a "Underperform" rating on 11/21/2025
- B of A Securities issued a "Underperform" rating on 11/10/2025
- JP Morgan issued a "Underweight" rating on 10/23/2025
- UBS issued a "Buy" rating on 10/23/2025
To track analyst ratings and price targets for Moderna, check out Quiver Quantitative's $MRNA forecast page.
Moderna Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 13 analysts offer price targets for $MRNA in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Eliana Merle from Barclays set a target price of $48.0 on 04/02/2026
- Edward Tenthoff from Piper Sandler set a target price of $69.0 on 02/23/2026
- Cory Kasimov from Evercore ISI Group set a target price of $35.0 on 02/17/2026
- Salveen Richter from Goldman Sachs set a target price of $41.0 on 02/17/2026
- Luca Issi from RBC Capital set a target price of $30.0 on 02/17/2026
- Eliana Merle from UBS set a target price of $34.0 on 01/07/2026
- Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
